NXL104

DRUG2 trials

Sponsors

Pfizer

Conditions

Healthy Male VolunteersHealthy Male and Female Japanese Volunteers

Phase 1

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

CompletedNCT01290900

PfizerHealthy Male Volunteers

Start: 2011-02-28End: 2011-05-31Updated: 2017-09-01

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

CompletedNCT01291602

PfizerHealthy Male and Female Japanese Volunteers

Start: 2011-02-28End: 2011-04-30Updated: 2017-09-01

Related Papers

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers.

2015-04-2824 citations

Randomized, placebo‐controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime–avibactam or ceftaroline fosamil–avibactam

The Journal of Clinical Pharmacology2013-10-2227 citations